Jasper Therapeutics, Inc.
JSPRNasdaq
$0.89
↑ +14.3%Jul 17 close · end-of-day
Price
1Y↓ -73.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.4M
Enterprise Value
$11.2M
P/E
—
P/S
—
P/B
7.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$20.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
590.2%
ROIC
—
Debt / Equity
—
Net Cash
$14.1M
Return 1Y
-73.7%
Company profile
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering. The company is based in Redwood City, California.
- CEO
- Ronald A. Martell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- www.jaspertherapeutics.com
Earnings
JSPR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.04↓ -97.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.7M | -$36.8M | -$51.2M | -$68.9M | -$76.2M | -$83.9M |
| Net income | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.80 |
| Diluted EPS | — | -$2.69 | -$10.33 | -$6.18 | -$4.89 | -$3.95 |
| Operating cash flow | -$18.3M | -$33.7M | -$45.9M | -$52.1M | -$62.6M | -$77.2M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.0M | -$19.9M | -$25.3M | -$21.8M | -$27.1M | -$19.2M | -$15.8M | -$11.0M |
| Net income | -$14.6M | -$18.6M | -$24.4M | -$21.2M | -$26.7M | -$18.7M | $66.7M | -$1.2M |
| Diluted EPS | -$0.97 | -$1.24 | -$1.65 | -$1.41 | -$1.74 | -$1.13 | $0.33 | -$0.04 |
| Operating cash flow | -$11.7M | -$14.1M | -$21.1M | -$22.8M | -$15.5M | -$17.0M | -$21.9M | -$14.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-22 | WIGGANS THOMAS G | Buy | 41,000 | $2.43 | $99,630.00 | filing |
| 2025-09-22 | MARTELL RON· President and CEO | Buy | 41,000 | $2.43 | $99,630.00 | filing |
| 2025-09-22 | Shizuru Judith Anne | Buy | 41,000 | $2.43 | $99,630.00 | filing |
| 2025-09-22 | Lucas Svetlana | Buy | 20,000 | $2.43 | $48,600.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.